EZH2 and osteosarcoma: Hornicek et al. have shown that EZH2 is essential for the growth and metastasis of osteosarcoma, and epigenetic therapy targetting EZH2 through specific inhibitors pharmacology can constitute a new method for the treatment of osteosarcoma [12].